No abstract available
Plain language summary
This study quantifies the revenue earned on all brand-name inhalers approved by the US Food and Drug Administration from 2000 to 2021 and compared earnings before and after expiration of primary patents on these products.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Drug Industry* / economics
-
Drug Industry* / legislation & jurisprudence
-
Drugs, Generic
-
Economic Competition* / economics
-
Nebulizers and Vaporizers* / economics
-
Patents as Topic* / legislation & jurisprudence
-
United States